Navigation Links
Neuralstem Responds to Incorrect StemCells, Inc. Release on Patents
Date:4/15/2008

ROCKVILLE, Md., April 15 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (Amex: CUR) today responds to an earlier press release by StemCells, Inc. by stating that StemCells, Inc. has completely mischaracterized the meaning of the US Patent and Trademark Office's most recent action.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"First," said Neuralstem President & CEO Richard Garr, "contrary to STEM's statement, the numerous substantial amendments made by STEM to get these two patents allowed completely destroy any basis for their assertions of infringement by Neuralstem.

"Second, I would like to remind everyone that the US Patent and Trademark Office upheld the patentability of Neuralstem's core technology in May, 2006, in response to a challenge from STEM. Our patents are not being challenged in this office action, nor in the suit which STEM brought against us.

"Finally, while we believe that any attempt by STEM to reopen their baseless law suit will be unsuccessful, as we asserted in our original response, Neuralstem does not infringe upon any of their "old" claims, nor do we infringe upon any of the significantly modified claims that they salvaged in the reexamination process."

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets. For further information, please visit http://www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the quarterly report on Form 10-KSB for the year ended December 31, 2007.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neuralstem Inc. Reports 2007 Third Quarter Financial Results and Events
2. Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
3. The Toy Industry Association Responds to Washington State Law Governing the Sale of Toys and the Governors Veto of Key Sections of the Bill
4. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
5. DRAXIS Responds to Trading
6. Maternal love: How a mothers brain responds to her infant
7. DuPont Responds to Spelter, W.Va. Lawsuit Rulings
8. Blue Cross of California Responds to Recent Media Coverage of Rescission
9. Veterans for Americas (VFA) Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report
10. Patient with rare disorder responds to cancer drug
11. Childhood Influenza Immunization Coalition Responds to Recent Influenza Outbreaks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , ... February 12, 2016 , ... According to an ... are beginning to account for a significant portion of hernia repairs throughout the United ... the Beverly Hills Hernia Center notes that this trend has not only been expected, ...
(Date:2/12/2016)... ... ... Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – ... who don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s ... But that takes time. , Take a close look at the warning letters the ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... AssureVest Insurance Group, ... is initiating a charity drive that will raise funds earmarked to purchase computers and ... Tayloe Elementary School. , “My school is in a low-income area and has more ...
(Date:2/12/2016)... ... 2016 , ... Donor Network West, the organ procurement organization that heals lives ... San Ramon Regional Medical Center. Under the collaboration, the first of its kind, specific ... a more certain time frame for donor families for the recovery of organs. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... On Thursday, Feb. 11, 2016, surgeons at ... North Austin Medical Center successfully completed the first robotic ... Surgical System with Trumpf Medical,s advanced operating table, ... , M.D., colorectal surgeon at the Texas Institute for ... Motion technology, which seamlessly combines the da Vinci Xi ...
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: